<DOC>
	<DOCNO>NCT01165333</DOCNO>
	<brief_summary>The aim study determine safety Cilengitide combination radiation therapy .</brief_summary>
	<brief_title>Cilengitide Combination With Irradiation Children With Diffuse Intrinsic Pontine Glioma</brief_title>
	<detailed_description>The prognosis child young adult malignant glioma brain stem recurrent malignant glioma ( whatever site ) poor . Over last decade , many therapeutic trial perform fail significantly improve survival patient . There thus need test new drug indication . There strong biological rationale use anti-angiogenic drug high-grade glioma . Cilengitide ( EMD121974 ; Merck KgaA , Darmstadt , Germany ) , cyclic pentapeptide contain sequence RGD ( cyclo- [ Arg-Gly-Asp-Dphe- ( NmeVal ) ] ) selective antagonist integrins αvβ3 αvβ5 , strongly involve tumour angiogenesis . Positive result Cilengitide preclinical model glioblastoma , particularly attractive safety profile encourage efficacy phase I II study adults child make potentially effective molecule treatment malignant glioma child . Furthermore , combination radiotherapy appear synergistic , without apparent increase toxicity . In study , Cilengitide evaluate concurrently administer radiotherapy first-line treatment maintenance monotherapy child young adult malignant brain stem glioma . The main objective determine maximum tolerate dose ( MTD ) Cilengitide administer twice weekly 60-minute intra-venous infusion .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Histologically confirm diffuse intrinsic pontine glioma Metastatic disease allow MRI measurable disease accord WHO criteria extension cohort Patient able undergo functional MRI ( diffusion , perfusion , spectro ) Patient able undergo FDGPET sestamibi SPECT Life expectancy &gt; 8 week start study treatment . No prior chemotherapy present cancer ; treatment cancer last 5 year . No prior cerebral radiation therapy Age &gt; 6 month &lt; 21 year Lansky Play Scale &gt; 50 ECOG Performance Status &lt; 2 ; NB : Children young adult bad performance status due gliomarelated motor paresis include . Absolute neutrophils count &gt; 1.5 x 109/l , Platelets &gt; 100 x 109/l Total bilirubin &lt; 1,5 x ULN , AST ALT &lt; 2,5 x ULN Serum creatinine ≤ 1,5 X ULN age . If serum creatinine &gt; 1,5 ULN , creatinine clearance must &gt; 70 ml/min/1.73 m² ( EDTA radioisotope GFR 24 hour urines collection ) Normal coagulation test : prothrombin rate ( prothrombin time = PT ) , TCA ( PTT ) , fibrinogen No current organ toxicity &gt; grade 2 accord NCICTCAE version 4.0 , especially cardiovascular renal disease ( nephrotic syndrome , glomerulopathy , uncontrolled high blood pressure despite adequate treatment ) . In case know possible cardiac disease , cardiological advice require prior inclusion study If anticonvulsant currently administer , dose regimen must stable within 1 week prior first dose Cilengitide If corticosteroid administer , dose regimen must stable ≥ 5 day prior first dose Cilengitide . Effective contraception patient ( male female ) reproductive potential entire participation study 6 month last administration Cilengitide . Negative pregnancy test ( serum betaHCG ) within 1 week prior start study treatment female reproductive potential Patient cover government health insurance Written inform consent give patient and/or parents/ guardian prior study participation Inclusion criterion failure History coagulation disorder associate bleed recurrent thrombotic event . Prior antiangiogenic therapy Any concomitant anticancer treatment foreseen protocol . Concomitant inclusion another therapeutic clinical trial ; participation another therapeutic clinical trial last 30 day . Pregnancy breast feed woman Uncontrolled intercurrent illness active infection Unable medical followup ( geographic , social mental reason )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Paediatric oncology</keyword>
	<keyword>Cilengitide</keyword>
	<keyword>Glioma</keyword>
</DOC>